Press Releases from Proteros biostructures GmbH (16 total)
PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND
Largest-ever Financing allows for Expansion of Drug Discovery Capabilities
MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company.
The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception…
Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration
Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology.
Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry…
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas.
At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for…
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global …
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services.
Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and…
Proteros has relocated to a tailor-made facility in Martinsried
Martinsried, October 24th 2011. Proteros biostructures GmbH is further extending its business capacities by moving into a new building in Munich-Martinsried, one of the leading Biotech locations in Germany.
After a two-year planning period, Proteros has reached an important milestone in its development by centralizing all operations within a purpose-built facility. The 4,000 square-meter of laboratory and office space, worth a total of about 15 M €, has been optimally designed…
Almirall enters into Integrated Discovery Agreement with Proteros
Barcelona, September 22, 2011. Almirall, S.A. and Proteros biostructures GmbH today announced they have entered into a research collaboration to identify small molecule inhibitors against a target selected by Almirall in the field of inflammatory diseases.
Under the agreement Proteros will apply its protein structure-based drug discovery platform. Proprietary site specific screening technologies, novel fragment libraries and structural biology will be deployed to support medicinal chemistry objectives of the program, to…
Rigel and Proteros renew X-ray protein crystallography collaboration
Martinsried, Germany, July 12, 2011. Proteros Biostructures GmbH (“Proteros”) announced today that it has renewed its agreement with Rigel Pharmaceuticals, Inc. (Rigel) to provide structural biology services for a Rigel drug discovery program.
Under this agreement, Proteros will provide X-ray structure analysis of protein-compound complexes for specific targets to support Rigel’s discovery efforts. Proteros will deploy its high throughput crystallography platform and proprietary technologies.
Proteros focuses on providing structure…
Proteros and Institut Pasteur Korea establish discovery services collaboration i …
Martinsried, Germany, May 24, 2011. Proteros Biostructures GmbH (Proteros) announced today that it has entered into a service agreement with Institut Pasteur Korea (IP-K) under which Proteros will provide structure-based drug discovery services to IP-K. Under this collaboration Proteros will apply its know-how, experience of structural analysis and its proprietary X-ray crystallography platform to support IP-K’s mission to develop therapeutics for infectious diseases.
Cony D’Cruz, Chief Business Officer of Proteros, stated,…
Proteros and Hutchison MediPharma enter into long-term research collaboration ag …
Martinsried, Germany, May 17, 2011. Proteros Biostructures GmbH (“Proteros”) announced today that they entered into a substantial research collaboration agreement with Hutchison MediPharma Limited (“HMP”), whereby Proteros will support HMP’s drug discovery process throughout 2011 and beyond.
Under the agreement Proteros initially will provide high quality crystallography services on certain projects to support HMP’s drug discovery projects. HMP is focused on the areas of oncology and autoimmune diseases. Proteros…
Proteros announces New Supervisory Board Appointments: Chairman David Lemus and …
Martinsried, Germany, May 10th, 2011. Proteros biostructures GmbH (Proteros) announced today a new supervisory board composition that is aligned with its growth and development objectives to become the preferred partner of choice for biotechnology and pharmaceutical companies seeking a high quality, reliable partner in drug discovery research services. Proteros’ platform enables ‘knowledge driven lead engineering’ to accelerate and improve protein structure analysis and structure-based lead discovery. The appointments will add…
Nimbus Discovery and Proteros enter into multi-target X-ray protein crystallogra …
Martinsried, Germany, March 23, 2011. Proteros Biostructures GmbH (“Proteros”) announced today that it has entered into a strategic collaboration with Nimbus Discovery, LLC (“Nimbus”) to deliver X-ray protein crystal structures for multiple targets.
Under the agreement, Proteros will provide structures from its Gallery Structure list, an ever growing catalogue of ready-to-use proteins (currently over one hundred) for rapid X-ray structure analysis of protein-ligand complexes in addition to providing gene-to-structure projects for…
Proteros and CHDI Foundation, Inc. establish discovery services collaboration to …
Martinsried, Germany, March 16, 2011. Proteros Biostructures GmbH (Proteros) announced today that it has entered into a service agreement with CHDI Foundation, Inc. (CHDI), under which Proteros will provide structure-based drug discovery services to CHDI. Proteros will apply its integrated discovery platform including proprietary X-ray crystallography tools to help CHDI in its mission to develop therapeutics that slow the progression of Huntington’s disease (HD).
Cony D’Cruz Chief Business Officer and President…
Proteros and University of Cincinnati, Drug Discovery Center establish collabora …
Martinsried, Germany, March 09, 2011. Proteros Biostructures GmbH (Proteros) announced today that it has entered into an agreement with University of Cincinnati, Drug Discovery Center (UC DDC), under which Proteros will provide biotech and pharmaceutical companies with access to UC DDC’s ultra-high-throughput and high-content screening platform coupled with a 340,000-plus library of drug-like compounds. Proteros will be responsible for all the client interactions and project management providing a single point…
Dr. Axel Ullrich, Director at the Max Planck Institute of Biochemistry, Martinsr …
Martinsried, Germany, February 21, 2011. Proteros Biostructures GmbH (“Proteros”) and Max Planck Institute (“MPI”) of Biochemistry, Martinsried announced today that Dr. Axel Ullrich has chosen Proteros as the preferred service partner to support kinase drug discovery research at the Department of Molecular Biology.
Proteros will develop kinase-focused assay systems and provide screening services employing its proprietary platform for screening to support the validation of novel kinase targets for drug discovery.
Dr.…
Proteros and SUPERGEN enter into an integrated lead discovery agreement
Martinsried, Germany, February 02, 2011. Proteros Biostructures GmbH (Proteros) announced today that it has entered into an agreement with SuperGen Inc., under which Proteros will collaborate on the discovery of small molecule lead compounds against a specific target of interest. Under the agreement, Proteros will deploy its integrated lead discovery platform that seamlessly links structural biology, screening of a tailor-made compound and fragment library, compound profiling and medicinal chemistry activities…
Proteros enters into a research agreement for structure based lead generation
Martinsried, Germany, September 27th, 2010. Proteros biostructures GmbH (Proteros) announced today that it has entered into an agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), under which Proteros will perform research to discover small molecule lead compounds against a specific target for delivery to J&JPRD. Under the agreement, Proteros will deploy its integrated Lead Discovery approach that interlinks structural biology, screening of a tailor-made in-house compound and…
